Présentation de l'entreprise
Cellectis S.A. operates as a clinical-stage biotechnological entity dedicated to the development of advanced products utilizing gene-editing technologies. The company focuses on creating a portfolio of allogeneic chimeric antigen receptor T-cells for immuno-oncology applications, alongside gene therapy candidates for other therapeutic indications. Within the broader financial landscape, Cellectis functions within the Healthcare sector and specifically the Biotechnology industry, positioning it among firms targeting high-value medical solutions rather than immediate mass-market pharmaceuticals. The organization employs a workforce of 224 individuals and holds a market capitalization of $357.10M with reported annual revenue of $79.59M. These valuation and revenue figures indicate that the company is a mid-sized entity within the biotechnology space, where significant capital is often required to advance products through clinical trials before generating substantial commercial cash flows, suggesting a capital-intensive operational model typical of the industry.
Santé financière
The company reported a revenue of $79.59M over the trailing twelve months, yet posted a net income of $-67,593,000 and an EBITDA of $-21,750,000. The substantial gap between the positive revenue of $79.59M and the negative net income reveals a cost structure where operating expenses significantly exceed gross profits, a common characteristic in the early development phases of biotechnology firms. Free cash flow stands at $-25,282,376, indicating that the company is burning cash to fund its research and development activities rather than generating liquidity from operations. This negative free cash flow implies limited financial flexibility for immediate debt repayment or large-scale acquisitions without external capital injection. Analyzing the margins provides further insight: the gross margin is 100.0%, which suggests that the cost of goods sold is negligible relative to revenue, likely due to the pre-commercial nature of the products; however, the operating margin is -142.1% and the profit margin is -84.9%, highlighting that overhead and R&D costs are eroding profitability well beyond the break-even point. On the balance sheet, the company holds $206.38M in cash against $86.69M in debt, supported by a debt-to-equity ratio of 114.22. While the absolute cash position exceeds debt obligations, the high debt-to-equity ratio indicates a leveraged balance sheet relative to shareholders' equity, reflecting the use of debt financing to support growth. The current ratio is 1.62, which indicates that the company possesses sufficient liquid assets to cover its short-term liabilities, maintaining a conservative stance regarding immediate liquidity solvency. Finally, the return on equity is -65.3% and the return on assets is -5.8%, metrics that reveal that management effectiveness, in terms of generating profit from capital, has been negative due to the heavy investment required to advance the clinical pipeline.
Évaluation de la valorisation
The valuation metrics present a mixed picture for investors analyzing the equity risk profile of Cellectis. The P/E Ratio (TTM) is N/A due to the negative earnings, while the Forward P/E is -5.73, a figure that is mathematically derived from projected earnings and implies expectations of continued losses or a specific turnaround narrative that is not yet realized in current performance. The price-to-book ratio stands at 3.38, indicating that the market values the company at a significant premium over its book value, which often reflects the intangible value of intellectual property and clinical pipeline potential rather than tangible assets. Alternative valuation measures such as the price-to-sales ratio of 4.49 and the EV/EBITDA of -6.34 suggest that the market is pricing in future growth potential rather than current profitability, as negative EV/EBITDA typically denotes a pre-profitability stage common in biotech. In terms of trading ranges, the 52-week high is $5.48 and the 52-week low is $1.17, meaning the current price sits somewhere within this wide volatility band, reflecting the binary nature of biotechnology stock performance. The beta value of 2.71 is critical for risk assessment, indicating that the stock price is expected to be highly volatile and move nearly three times as much as the broader market in either direction, making it unsuitable for risk-averse portfolios.
Growth & Income
The growth profile for Cellectis is characterized by a contraction in top-line performance, with revenue growth (YoY) at -19.5% and earnings growth (YoY) listed as N/A due to the absence of positive net income. Since earnings are negative, the concept of earnings growing faster than revenue does not apply in a traditional sense, but the decline in revenue suggests a challenge in scaling commercial operations or managing sales cycles effectively in the current fiscal year. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This strategy confirms that the company reinvests all available earnings and cash reserves directly back into the business to fund clinical trials and product development rather than paying dividends. The overall growth and income profile for Cellectis S.A. is defined by a focus on capital reinvestment for long-term technological advancement rather than providing current income or consistent revenue expansion at this stage of development.